The enthusiasm over FDA approval for Teva's migraine treatment has waned.
American industry commentator Adam Feuerstein shouted what many whisper - but the horror isn't just one way.
Only 10% of Teva's shares are owned by Israelis and after the cuts only 8% of employees will be Israeli.
Continuous treatment of Parkinson's disease will enable patients to tolerate the drugs better for longer.
Compugen shows life sciences companies that invest heavily in science can achieve a breakthrough, even after the capital market has given up on them.
Biotech billionaire Prof. Shlomo Ben-Haim is facing his third lawsuit this year and fourth in his career over the life sciences companies he founded.
Given Imaging told the US Food and Drug Administration (FDA) today that it will not be seeking the replacement of colonoscopies with its pill.
New Teva CEO Dr. Jeremy Levin has already said that part of his strategy will be greater "budgetary discipline."
The eventual expiration of Copaxone's patents will still cause a huge hole in Teva's revenue and profits.